OWC Pharmaceutical Research Corp (OWCP)

[EasternTimeZone]

The Monaco Growth Forums next week will be huge for OWCP. It says a lot that Dr. Yehuda Baruch, Chief Science Officer of OWCP is considered as the world renowned leader in the sector of Cannabis bio-pharma research and will be a speaker at this prestigious event. Many deep pockets will be hearing from the man himself and it is very likely that big investors will invest in OWCP. Good days ahead.

Speakers
https://monacogrowthforums.com/speakers/

OWC Pharmaceutical Research Corp. to Present at Monaco Growth Forums in Monaco
Spring Edition to Take Place 25th-26th April 2017

PR Newswire
PETACH TIKVA, Israel, April 17, 2017

The Monaco Growth Forums by Andreea Porcelli and OWC Pharmaceutical Research Corp. (OTC: OWCP), are pleased to announce that OWCP has been invited to present at the Monaco Growth Forums Spring, Edition, on April 25th - 26th at The Montepole Hotel in Monte Carlo, Monaco. During the event, management will introduce OWC Pharmaceutical's approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP's CSO& CTO will also be a Keynote Speaker at MGF's Cocktail Reception on Wednesday, April 26th. The keynote topic will be "Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.

Through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis.

Mr. Mordechai Bignitz, Chairman and CEO commented, "We are very excited to participate in this prestigious European event and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first. After publishing our recent news regarding the Pre-Clinical efficacy study findings, concluding that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis, we received active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We anticipate that together with some states in the U.S. and Canada. Europe can soon become a primary market for our products.

"Andreea Porcelli, CEO and Founder of Monaco Growth Forums commented, "We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area."

For more information or to RSVP for the MGF Spring Conference event and one-on-one investor meetings with OWC Pharmaceutical Research Corp., contact Sevinc Bermek, Events Coordinator: [e-mail] or visit https://monacogrowthforums.com/ .

About OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/

About Monaco Growth Forums by Andreea Porcelli Ltd.

Monaco Growth Forums (MGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andreea Porcelli, MGF Founder, and President has more than 20 years experience as an international investment banker, finding investors for small cap companies on a world scale. She and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high-net-worth individuals, and industry-related sponsors and foundations-all of whom are also exclusively invited to match MFG's highly selective criteria. http://www.monacogrowthforums.com



Another article about this event.
http://oracledispatch.com/2017/04/18/owc-pharmaceutical-research-corp-otcmktsowcp-pops-front-key-monaco-appearance/

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Pops in Front of Key Monaco Appearance
By Jermaine Farmer - April 18, 2017
SHARE Facebook Twitter
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is a penny play in the cannabis patch that’s clearly begun to spur some interest among players in the marketplace as shares bounce up off recent lows. The principal catalyst, we believe, is likely the development that the company is going to be a presenter at the Monaco Growth Forum next week, and the company’s Chief Science Officer is slated to be a keynote speaker.

Given that the company now has real data to discuss where efficacy of its psoriasis cream is concerned, one might see this as a good venue for management to make some more important announcements either about data or upcoming clinical study plans. It’s plausible to see the recent action as a reflection of this idea, particularly as the company’s spot at the event was likely available in some form on Friday (such as the Forum’s schedule page), when the stock went berserk on the upside.

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) casts itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.

OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.

All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

OWCP’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.

Find out when OWCP stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.



As noted above, OWCP has been “invited to present at the Monaco Growth Forums Spring Edition, on April 25th – 26th at The Montepole Hotel in Monte Carlo, Monaco.”

During the event, management will introduce OWC Pharmaceutical’s approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP’s CSO& CTO will also be a Keynote Speaker at MGF’s Cocktail Reception on Wednesday, April 26th.

According to the release, the keynote topic will be “Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.”

Mr. Mordechai Bignitz, Chairman and CEO commented, “We are very excited to participate in this prestigious European event and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first. After publishing our recent news regarding the Pre-Clinical efficacy study findings, concluding that post-application of OWC’s unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis, we received active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We anticipate that together with some states in the U.S. and Canada. Europe can soon become a primary market for our products.

Traders will note 31% added to share values of the company over the past week of action, but that move comes in the context of a larger bearish trend. That said, OWCP has a track record that includes a number of dramatic bounces. In addition, the stock has seen an influx in interest of late, with the stock’s recent average trading volume running 85% over what the stock has registered over the longer term.